StockWatch
·

Honasa Consumer Ltd Q2 FY27 Results

HONASAQ2 FY27 Results
Filing
Result:Very Good· Market: Down#Margin expansion

Beat/Miss: Beat · Outlook: Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue731.193.3%35.9%
Total Income752.943.3%34.9%
Expenditure652.411.0%29.1%
PBT100.5315.7%90.6%
Net Profit73.2519.0%86.7%
OPM12.71%1.87pp3.86pp
NPM9.73%1.89pp2.70pp
EPS2.2419.1%85.1%
View full financials

FMCG core metric (revenue) grew 36% YoY with EBITDA margin expanding ~385bps and PAT nearly doubling, clearing the Street's margin bar for a beat — a standout quarter, tempered only by the expected sequential seasonal cooling.

HONASA CONSUMER · Q2 FY-27 · THE VERDICT

36% Growth, But PAT Fell 19% QoQ—Investment Tempo Exceeds Margin Realization

Honasa delivered its highest revenue growth since IPO (36% YoY), doubled EBITDA absolute, and maintained OPM at 12.7%. But PAT fell 19% QoQ despite higher sales—a signal that management is front-loading investment to lock in the 15% EBITDA target. The question now is whether margin expansion begins in H2 or remains compressed through FY27.

10 Nov 2026 · 6 min read
Revenue YoY

₹731 Cr

+35.9% (claimed 36%)

PAT YoY

₹73 Cr

+86.7%; but -19% QoQ

OPM

12.7%

Held stable; EBITDA doubled

On the surface, Q2 looks like a blowout: ₹731 crore in revenue—highest growth quarter since IPO—with PAT up 86.7% year-on-year and EBITDA doubled in absolute terms. The headline OPM held at 12.7% despite crude oil and packaging cost headwinds. But look at the sequential picture: PAT fell 19% from Q1 (₹90.3 Cr → ₹73.2 Cr) even as revenue rose. That gap—growth without earnings lift—is the story of the quarter. Management is investing aggressively (A&P, capex for younger brands, hair color entry) to achieve the stated 15% EBITDA target over four years via 100–150 bps annual expansion. Near-term earnings are paying the price.

Management claims vs. what holds up

Grading each key claim against the delivered result

36% net sales growth, highest quarter since IPO

Supported

Revenue ₹731.2 Cr, +35.9% YoY

Doubled EBITDA, held 12.7% OPM profile

Supported

OPM 12.7% delivered; EBITDA growth via volume, not leverage

PAT growth strong via UVG 31.3%, A&P/mix 250–270 bps delta

Overstated

PAT +86.7% YoY; but -19% QoQ; investment tempo exceeds margin realization

Younger brands 40%+ growth ex-The Derma Co.

Supported

Claimed and corroborated; BBlunt 100%+, Staze, Dr. Sheth's, Aqualogica tracking

Mamaearth 26% YoY growth, 40% modern trade offtake

Supported

3.2 lakh outlets, strong trajectory both online/offline

Focus categories now 80%+ of revenue

Supported

Up from 70% historically; face wash, shampoo, sunscreen, moisturizers all 20%+ growth

What changed on this call

Management reaffirmed the 15% EBITDA margin target but extended the timeline to four years (vs. annual cadence implied earlier). This is a subtle retreat on urgency but a clearer commitment to the path: 100–150 bps annual expansion via A&P efficiency (250–270 bps realized), operating leverage (110–140 bps unlocked), and channel mix (offline 40%+ growth vs. e-comm 20%+). Focus category contribution jumped from 70% to 80%+ of revenue—a strategic shift toward higher-margin categories. Hair color entry via BBlunt is new: the brand is growing 100%+ within a ₹50K crore market where Honasa holds ~5% share, providing significant headroom. Younger brands (excl. The Derma Co.) sustained 40%+ growth, proving the portfolio expansion is not a one-quarter anomaly.

The bull case

Honasa proved it can grow at 36% while defending margins. Q2 revenue of ₹731 crore is the strongest quarter in 12 post-IPO, with EBITDA doubled in absolute terms and OPM held at 12.7% despite external headwinds. The drivers are concrete: UVG 31.3% (volume not just price), A&P efficiency 250–270 bps (marketing productivity), operating leverage 110–140 bps (scale benefits), and channel mix shift (modern trade 40%+ offtake vs. e-comm 20%+). The multi-brand portfolio is working. Mamaearth (₹1000+ Cr equivalent, 3.2 lakh outlets) grew 26% ND with strong modern trade traction; The Derma Co. is profitable and scaling; younger brands (BBlunt, Staze, Dr. Sheth's, Aqualogica) are collectively 40%+ and capturing Gen Z + premium segments. Focus categories are now 80%+ of revenue, a more profitable mix than the 70% baseline. Hair color entry (₹50K Cr market, ~5% share) is a multi-year growth vector. BBlunt is already 100%+ growth; management promises a second hair brand entry soon, doubling down on a category where Honasa can scale innovation. The 15% EBITDA target over four years is credible. Management has already unlocked 150–200 bps of operating leverage (A&P + scale); the remaining path to 15% is 200–300 bps, achievable via younger brand scaling (margin accretion) and new category mix.

The bear case

PAT fell 19% QoQ despite 36% revenue growth—a red flag that investment is outpacing margin realization. Q2 reported ₹73.2 Cr PAT, down from ₹90.3 Cr in Q1, even though revenue was higher. This signals management is front-loading A&P spend, capex for younger brands, and hair color launch costs. If this pattern continues through H2 (seasonally higher spend in Q3–Q4 per management), FY27 PAT growth will disappoint well below the 86.7% YoY Q2 delivered—a material miss for earnings-driven investors. Mamaearth base maturation is a risk. The brand now has 3.2 lakh outlets and ₹1000+ Cr equivalent revenue; sustaining 26% ND growth through a higher H2 base is uncertain. Management claimed "high-teen growth equally there on both online/offline," but high-teens from a ₹1000 Cr base is a different beast than high-teens from ₹500 Cr. Hair color entry is competitive with sparse go-to-market clarity. BBlunt growing 100%+ is impressive, but the market is dominated by entrenched players (Garnier, LOréal, Revlon). Management promised a second hair brand "soon" but offered no timeline or positioning. E-commerce growth is decelerating. Q2 e-comm grew 20%+ vs. offline 40%+; this suggests online channel saturation or competitive intensity. If this continues, Honasa's high-margin D2C channels may face headwinds. FY27 guidance is vague. Management said FY27 would "exceed historical ranges" but disclosed no explicit net profit target, making it impossible to grade delivery. Near-term margin is stuck. Management guided toward 12.5% EBITDA near-term, with margin expansion deferred to 4 years; investors betting on near-term EPS expansion will be disappointed.

How the street is positioned

The stock is near all-time high but has pulled back 11.5%. At ₹484.05, Honasa sits above its SMA20 (₹454.25), SMA50 (₹462.1), and SMA200 (₹394.48)—a bullish trend. But it's 11.51% below its all-time high of ₹547, suggesting profit-taking post-result or macro headwinds. RSI at 61 is neutral (not overbought), and volume is increasing—a sign of accumulation rather than distribution. The pullback reflects the market's own ambivalence: headline growth is impressive, but QoQ PAT compression is a concern.

Institutional ownership is mixed. FII trimmed -0.1pp to 13.64% (from 13.74% a quarter ago), while DII added +2.34pp to 21.58% (from 19.24%). This is classic: foreign investors are cautious on near-term earnings, while domestic institutions are adding on the long-term story. VC/PE are liquidating. Recent bulk deals show SEQUOIA CAPITAL and PEAK XV PARTNERS selling ~₹450 levels in September, while FRANKLIN TEMPLETON and ICICI PRUDENTIAL LIFE are buying. This is standard post-maturation dynamics: early-stage investors are harvesting gains, while long-term domestic players accumulate. Promoter stake is stable at 35.47% (FY27 Q1), so no insider-selling red flag. The market verdict: Honasa's story is credible, but the near-term margin compression is a temporary drag. Domestic institutions see 4-year value; foreign investors are staying on the sidelines until margins stabilize.

The debate

The bull-bear ledger
  • Highest revenue growth quarter in 12 since IPO (36% YoY, ₹731 Cr)

  • EBITDA doubled absolute; OPM held 12.7% despite crude/cost headwinds

  • A&P efficiency 250–270 bps + operating leverage 110–140 bps unlocking

  • Younger brands 40%+ growth; multi-brand portfolio (Mamaearth, Derma Co., BBlunt, Dr. Sheth's) working

  • Offline channel 40%+ modern trade growth; Mamaearth same-store ~30% growth

  • Hair color market entry (₹50K Cr, ~5% share); BBlunt 100%+ growth

  • Focus categories 80%+ of revenue (vs 70% historically), more profitable mix

  • 15% EBITDA target over 4 years with concrete mechanisms (channel, A&P, leverage)

  • PAT fell 19% QoQ despite revenue growth; investment spending outpaces margin realization

  • Mamaearth base (₹1000+ Cr, 3.2 lakh outlets) maturing; sustaining 26% ND through H2 uncertain

  • E-commerce growth decelerating (20%+ vs 40%+ offline); channel saturation risk

  • Hair color entry is competitive; second brand entry timeline and positioning vague

  • No explicit FY27 net profit guidance; only qualitative 'exceed ranges'

  • Near-term margin stuck at ~12.5%; 4-year path to 15% leaves limited near-term EPS upside

  • Younger brands Gen Z, urban-focused; rural/lower-income penetration unproven

Risks, ranked by holder concern

What should concern you most if you hold Honasa

Margin expansion execution: can operating leverage (110–140 bps) sustain while investing in younger brands and hair color?

High

Q2 PAT fell 19% QoQ despite revenue growth. If H2 follows suit, FY27 PAT will disappoint well below 86.7% YoY. The 15% EBITDA target assumes margin expansion locks in; if investment spend continues to compress PAT, the credibility of the path falters.

Mamaearth base maturation: sustaining high-teens growth through H2 with higher base

Medium

26% ND growth from ₹1000+ Cr base is strong, but 3.2 lakh outlets and offline reach are mature metrics. H2 comp base is higher; management claimed "high-teen growth equally on both channels," but high-teens on a ₹1000 Cr base is a different beast.

Hair color market entry: competitive market; BBlunt momentum may not sustain, and second brand entry is undisclosed

Medium

Entrenched players (Garnier, LOréal, Revlon) dominate. BBlunt 100%+ growth is impressive but may reflect new-product lift. Long-term share risk if pricing or distribution falters. Second brand entry promised "soon" with no timeline or positioning.

E-commerce growth deceleration (20%+ vs 40%+ offline); online saturation or competitive intensity

Medium

D2C channels were a margin lever for Honasa; if e-comm growth continues to moderate, Honasa loses a high-margin growth vector. Channel shift to offline is positive for mix but suggests online market maturity.

Macro BPC sensitivity: urban-focused portfolio dependent on discretionary spending

Low

Younger brands (BBlunt, Staze, Dr. Sheth's) are Gen Z and urban-skewed. Macro slowdown could soften demand. Mitigated by structural tailwinds (women workforce, male BPC adoption), but not immune.

What to watch next

The 2–3 concrete things that resolve the debate
  • 1 · Q3 EBITDA margin

    Will EBITDA margin hold at 12.5% or expand toward 13%? Q3 is seasonally strong (festive) but typically sees higher A&P spend. If margin expands despite investment, it validates the 4-year path. If it compresses further, investors should worry about achieving 15%.

  • 2 · Mamaearth H2 growth trajectory

    Can 26% ND growth hold through Q3–Q4 high base, or does it decelerate to low-teens? Management claimed "high-teen growth equally on online/offline." Q3–Q4 earnings and call comments will validate whether base maturation is a real risk.

  • 3 · Hair color category scaling

    What % of total revenue is BBlunt by FY28? If it scales to 5%+ of sales, it validates the category entry strategy. Also watch for second brand launch timing and positioning—will it be soon (next 2 qtrs) or deferred to FY28?

  • 4 · Focus category mix and profitability

    Focus categories are now 80%+ of revenue; can the company expand to 85%+ while maintaining growth? More importantly, are these high-margin categories expanding faster than lower-margin categories? This is the real lever for long-term margin expansion.

The single number to track from here

EBITDA margin, not PAT or revenue. Honasa's story lives or dies on achieving 15% EBITDA over four years via 100–150 bps annual expansion. Q2 held at 12.7%; watch whether it expands to 13% by Q3, 13.5% by Q4, and approaches 14% by FY28. If EBITDA margin starts expanding visibly (even modestly, +25–50 bps per quarter), it validates the investment timing and unlocks long-term value. If it stays flat or compresses, the bull case fractures. Investors should measure Honasa's progress against the EBITDA margin path, not headline revenue growth.

Honasa's Q2 result is a high-quality quarter that masks a timing tension: the company is investing aggressively to achieve long-term margin expansion, but near-term earnings are paying the price. PAT fell 19% QoQ despite 36% revenue growth—a signal that management is prioritizing margin architecture over EPS near-term. The 15% EBITDA target over four years is credible and achievable, but the path is lumpy.

For holders, the question is not whether Honasa can grow revenue—it clearly can—but whether margin expansion locks in. H2 earnings will be lumpy with investment spend; the real proof points are Q3–Q4 EBITDA margin (watch for expansion toward 13%), Mamaearth H2 growth (sustaining high-teens validates the growth narrative), and hair color scaling (validating the new category entry). At ₹484, the stock is fairly valued on the long-term story but offers limited near-term EPS upside. Wait for Q3 results to see if margin expansion begins; that's when conviction should build.

The honest read: Honasa is a step-change business with credible long-term potential, but near-term is about margin execution, not revenue. The number to track is EBITDA margin—watch whether it expands from 12.7% toward 13–13.5% in the next 2–3 quarters. Until then, the stock is a hold for long-term believers and a wait for near-term traders.

Informational and educational content only. Not investment advice.